@article{JGO20784,
author = {Victor Hugo Fonseca de Jesus and Marcos Pedro Guedes Camandaroba and Mauro Daniel Spina Donadio and Audrey Cabral and Thiago Pimentel Muniz and Luciana de Moura Leite and Lucas Ferreira Sant’Ana},
title = {Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma},
journal = {Journal of Gastrointestinal Oncology},
volume = {9},
number = {4},
year = {2018},
keywords = {},
abstract = {Background: FOLFIRINOX stands a major breakthrough in the management of metastatic pancreatic adenocarcinoma (MPA). Nonetheless, significant side-effects have been reported using standard FOLFIRINOX. We aimed to compare survival outcomes, response rates and toxicity of patients treated with standard or modified FOLFIRINOX in MPA.
Methods: We included patients aged ≥18 years old, with pathologically confirmed MPA, treated with FOLFIRINOX in the first-line setting. Patients submitted to at least one cycle of full-dose FOLFIRINOX were grouped in the standard FOLFIRINOX group.
Results: Patients treated with standard FOLFIRINOX were younger and had less comorbidity. We observed no differences in overall survival or in progression-free survival between the two treatment arms. The only variable independently associated with OS was log10[neutrophil-to-lymphocyte ratio (NLR)]. Modified FOLFIRINOX was associated with a lower dose reduction rate, but a slightly increased incidence of severe toxicity.
Conclusions: Modified FOLFIRINOX presents the same activity against MPA as standard FOLFIRINOX. We found no significant differences in toxicity, possibly due to patient selection and a higher dose reduction rate in the standard FOLFIRINOX arm. NLR stood as an important prognostic marker and further research is needed to comprehend its biological meaning in pancreatic cancer.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/20784}
}